

**PATIENT**

Teddy Fink

**SPECIES**

Canine

**BREED**

Great Pyrenees Mix

**SEX**

Neutered Male

**AGE**

14 Years

**WEIGHT**

85 Pounds

**INTERPRETED BY**

Eric Lindquist, DMV,  
DABVP, Cert. IVUSS

**HOSPITAL NAME**

Q Street AH

**REFERRING VET**

Dr. Bretschneider

**INVOICE NUMBER**

14668

**DATE**

4/8/22

**PRESENTING CLINICAL SIGNS**

History: Persistent Hematuria and moderate straining to urinate in spite of 2 courses of antibiotics. The urine was cultured prior to the second antibiotic. Bacteria grew and sensitive to both Enrofloxacin and Sulfa (which are the antibiotics that we used). Concerned that there is a bladder stone or tumor harboring infection. Also losing weight and not very interested in food  
Current Medications Sulfamethoxazole and Trimethoprim 480 mg 1 1/4 PO BID  
Primary Question/Differential to Be Answered in This Exam see if there is a bladder tumor or stone and/or screen for neoplasia/ organ disease in the abdomen that could be causing weight loss/ loss of appetite

Abnormal PE/Chem/CBC/UA Results: CBC and Chemistry are unremarkable

**ULTRASONOGRAPHIC EXAMINATION OF THE ABDOMEN**

**Urinary System**

The caudal aspect of the **urinary bladder** revealed an extensive mass, occupying the cystourethral junction and proximal urethra. Concurrent bladder sand was noted.

The **prostate** was enlarged, irregular and heterogeneous, measuring 2.32 cm. The prostate revealed areas of mineralization, creating a mass effect. Regional pericapsular inflammation was present.

The **kidneys** revealed largely normal size and structure, corticomedullary definition and ratio (cortex 1/3 of medulla) were essentially maintained with some minor age-related loss of curvilinear patterns regarding the capsule and C/M junction. The cortices presented largely uniform texture with some increased echogenicity expected for his age patient. Medullary structure differed distinctly from that of the cortex and no evidence of pelvic dilation was present. The right kidney measured 7.05 cm. The left kidney measured 7.78 cm.

**Adrenal Glands**


Both **adrenal glands** were visualized and recognized as having normal shape, size, position and echogenicity for this breed. The phrenic vasculature, glandular echogenicity and detail were unremarkable. Capsule, cortex, and medullary definition were normal for this age patient. The right adrenal gland measured 3.47 cm x 1.33 cm at the cranial pole and 0.67 cm at the caudal pole. The left adrenal gland measured 2.91 cm x 0.51 cm at the cranial pole and 0.61 cm at the caudal pole.

**Spleen**

The **spleen** presented a smooth homogeneous parenchyma hyperechoic to liver and renal cortical parenchyma. The capsule was smooth without noticeable expansion or deviation from within the spleen or adjacent pathology. The splenic vasculature demonstrated normal volume without signs of congestion or thrombosis. No sonographic evidence of acute or chronic inflammatory, neoplastic, or infarctual changes were noted.

**Liver**

The **liver** images submitted revealed subjectively normal liver size, contour, and structure. Parenchymal echogenicity was naturally coarse and hypoechoic to the spleen. Vascular and



**PATIENT** biliary tracts were of normal volume with no evidence of congestion. The gallbladder presented acceptably thin walls with primarily anechoic content. The cystic and common bile ducts were normal. No pathological hepatic lymphadenopathy was evident. No overt structural evidence of inflammatory, infiltrative or regenerative pathology was evident.

Teddy Fink

**SPECIES** **Gastrointestinal**  
Examination of the **gastrointestinal tract** revealed a stomach and intestine free of stasis, of normal wall thickness, acceptable curvilinear mural detail, and peristaltic activity. Small and large intestine demonstrated normal luminal chyme and stool consistency respectively. No obstructive or overt infiltrative disease was noted. No associated abnormal lymphatic activity was noted.

Canine

**BREED** **Pancreas**  
The base and limbs of the **pancreas** were observed to be largely isoechoic to surrounding omental fat. Pancreatic duct and capsular contour were acceptably normal and parenchyma respected normal curvilinear patterns. No overt evidence of active inflammatory or neoplastic disease was noted.

Great Pyrenees Mix

**SEX**  
Neutered Male

**ULTRASONOGRAPHIC FINDINGS**

**AGE**

- Urinary bladder and prostatic carcinoma pattern/masses
- Geriatric abdomen otherwise

14 Years

**INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

**WEIGHT** Referral for chemotherapeutic intervention and stent placement would be appropriate. No evidence of metastatic disease beyond the prostate and lower urinary tract.

85 Pounds


**INTERPRETED BY**  
Eric Lindquist, DMV,  
DABVP, Cert. IVUSS


**HOSPITAL NAME**  
Q Street AH

**REFERRING VET**  
Dr. Bretschneider

**INVOICE NUMBER**  
14668

**DATE**  
4/8/22





**PATIENT**

Teddy Fink

**SPECIES**

Canine

**BREED**

Great Pyrenees Mix

**SEX**

Neutered Male

**AGE**

14 Years

**WEIGHT**

85 Pounds

**INTERPRETED BY**

Eric Lindquist, DMV,  
DABVP, Cert. IVUS

**HOSPITAL NAME**

Q Street AH

**REFERRING VET**


Dr. Bretschneider

**INVOICE NUMBER**


14668

**DATE**

4/8/22



The information and recommendations provided are based on the images presented by



**PATIENT** the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Teddy Fink

Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

**SPECIES**

Canine **Eric Lindquist**, DMV, DABVP, Cert. IVUSS, CEO of SonoPath.com  
Eric.Lindquist@SonoPath.com

**BREED**

Great Pyrenees Mix

**Canine Prostatic Neoplasia**

<http://www.sonopath.com/ProstaticCarcinoma>

**SEX**

Neutered Male

**Description:** Prostatic neoplasia is frequently seen in dogs and can be diagnosed via ultrasonographic examination. The most commonly diagnosed prostatic neoplasms are adenocarcinoma and undifferentiated carcinoma. Transitional cell carcinoma (TCC) frequently spreads from the urinary bladder and urethra to the prostatic tissue (see the “Transitional Cell Carcinoma” chapter for more details). Metastatic squamous cell carcinoma, lymphoma, hemangiosarcoma, and leiomyosarcoma have been reported, but are less prevalent. Prostatic neoplasia has been documented in cats, but is quite rare.

**AGE**

14 Years

**Clinical Signs:** Prostatic neoplasia presents in both neutered and intact males; however, a 2002 study suggested that neutered males were at greater risk for developing prostatic neoplasia than intact males. Typically, prostatic neoplasia is seen in older dogs (mean age of 10 years). Breed predilection includes mixed breed dogs, Shetland Sheepdogs, Dobermans, Scottish Terriers, and Airedale Terriers. Clinical signs and commonly reported signs from owners typically include: stranguria, frequent urinations, hematuria, dyschezia, weight loss, and decreased appetite. Other findings upon physical examination include fever, ataxia, pain upon rectal examination, and pain upon spinal palpation.

**WEIGHT**

85 Pounds

**Diagnostics:** Ultrasonographic examination should be performed if prostatic neoplasia is suspected. Common ultrasonographic findings include an enlarged, irregular prostate that typically has a hypoechoic appearance. Multifocal, poorly coalescing hyperechoic foci are also seen in prostatic malignancies. Hyperechoic foci are due to mineralization of the prostate; they cause far field shadowing. Cystic components can also be observed and are thought to indicate abscessation and/or necrosis. It can be difficult to differentiate chronic bacterial prostatitis from a prostatic neoplasia; however, regional lymphadenopathy is much more common with prostatic neoplasia than it is with chronic bacterial prostatitis. Malignancies of the prostate have often metastasized by the time of diagnosis. Frequent sites of metastases include the sublumbar lymph nodes, the pelvis, lumbar vertebrae, and the lungs. If metastases to the pelvis or lumbar vertebrae have occurred, bony lysis will often be noted radiographically. Metastasis to the liver, brain, kidney and spleen may occur. A definitive diagnosis of a prostatic neoplasm can be achieved through biopsy as well as fine needle aspiration (FNA) or through ultrasound-guided traumatic catheterization.

**INTERPRETED BY**

Eric Lindquist, DMV, DABVP, Cert. IVUSS

**HOSPITAL NAME**

Q Street AH

**REFERRING VET**

Dr. Bretschneider


**INVOICE NUMBER**

14668


A complete and thorough workup includes a CBC, biochemical profile, urinalysis, as well as three radiographic views of the thorax, an abdominal ultrasound, and an ultrasound-guided prostatic biopsy or FNA, if indicated. Urinalysis may reveal hematuria and pyuria. Prostatic fluid analysis can also be helpful in identifying neoplastic cells.

**DATE**

4/8/22



<b>PATIENT</b>	<b>Treatment:</b> Unfortunately, once diagnosed, prostatic carcinoma offers a poor prognosis; prostatectomy, chemotherapy, and radiation therapy have proven unsuccessful in improving quality or length of life. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as deracoxib, meloxicam, and piroxicam, have been used for their palliative, anti-neoplastic properties with prostatic carcinomas. Certain tumors, including various carcinomas (e.g. TCC, prostatic carcinoma, mammary carcinoma, squamous cell carcinoma) overexpress COX-2, which converts arachidonic acid to prostaglandin G2 (PGG2)/prostaglandin H2 (PGH2), and ultimately to prostaglandin E <sub>2</sub> (PGE <sub>2</sub> ). The metabolite, PGE <sub>2</sub> , is associated with increased inflammation, tumor invasiveness, angiogenesis, and reduced apoptosis. In vivo and in vitro, NSAIDs inhibit COX-2, resulting in the suppression of PGE <sub>2</sub> , and thereby inhibiting tumor growth and metastasis. This effect has been achieved with both non-selective COX inhibitors as well as COX-2 inhibitors (the latter will suppress COX-1 at increased doses).
Teddy Fink	
<b>SPECIES</b>	Some cases of prostatic carcinoma are managed palliatively with cyst/abscess ultrasound-guided drainage, antibiotic infusion, systemic antibiotics, and NSAID treatment and/or chemotherapy. Anecdotally, it has been observed that patients that often present clinical signs of hematuria or dysuria owing to cyst or abscess formation may be treated with repeat ultrasound-guided drainage. This appears to work especially well if there is a considerable cystic component to the prostatic tumor. The key is to image the prostate adequately, drain any cysts that are present, sample the abnormal parenchyma (FNA or biopsy), and potentially infuse antibiotics directly into the cystic cavities if a suppurative fluid is retrieved. The patient should be monitored clinically over time and reevaluated to see if cysts recur. Every case responds differently to treatment, and the behavior of parenchymal and cystic growth will vary.
Canine	
<b>BREED</b>	Currently, investigational studies involving fluoroscopic-guided direct chemotherapeutic embolization through the iliac arteries as well as urethral stent placement are offered by select tertiary veterinary facilities that have an interventional radiology department. Ultrasound-guided endoscopic diode laser ablation through a perineal urethrostomy is also being attempted as a salvage and palliative procedure.
Great Pyrenees Mix	
<b>SEX</b>	<b>Conclusion:</b> Prostatic neoplasia is more commonly detected in neutered male dogs than intact males. Diagnosis is typically obtained using ultrasound, cytology, and histopathology. Unfortunately, traditional therapy typically yields a guarded to poor long-term prognosis, but palliation with NSAIDs and/or chemotherapy can temporarily improve clinical signs. Investigational techniques may provide additional therapeutic options but are currently experimental.
Neutered Male	
<b>AGE</b>	<b>References:</b>
14 Years	<p>Cerf DJ, Lindquist EC. Palliative ultrasound-guided endoscopic laser ablation of transitional cell carcinomas of the lower urinary tract in dogs. <i>J Am Vet Med Assoc</i> 2012;240(1):51-60.</p> <p>Culp, WTN. Interventional oncology and the management of urinary tract cancer. Proceedings from the American College of Veterinary Internal Medicine, New Orleans, LA, May 30-June 2, 2012.</p> <p>Francey T. Prostatic Diseases. In: Ettinger SJ, Feldman EC, eds. <i>Textbook of Veterinary Internal Medicine 7th ed.</i> Philadelphia, PA: WB Saunders; 2010:2047-58.</p>
<b>WEIGHT</b>	
85 Pounds	
<b>INTERPRETED BY</b>	
Eric Lindquist, DMV, DABVP, Cert. IVUSS	
<b>HOSPITAL NAME</b>	
Q Street AH	
<b>REFERRING VET</b>	
Dr. Bretschneider	
<b>INVOICE NUMBER</b>	
14668	
<b>DATE</b>	
4/8/22	



**PATIENT**

Hecht S. Male Reproductive Tract. In: Pennick D, D'Anjou MA, eds. *Atlas of Small Animal Ultrasonography*. Ames, IA: Blackwell Publishing; 2008:417-43.

Teddy Fink

Milner RJ. Do NSAIDs make a difference in cancer. Proceedings from the American College of Veterinary Internal Medicine, Denver, CO, June 15-18, 2011.

**SPECIES**

Mohammed SI, Khan KN, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. *Prostag Leukotr Ess* 2004;70(5):479-83.

Canine

Nyland, TG, Matton JS. *Small Animal Diagnostic Ultrasound 2nd ed.* Philadelphia, PA: WB Saunders; 2002:250-66.

**BREED**

Sorenmo KU, Goldschmidt MH, Shofer FS, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. *Vet Comp Oncol* 2004;2(1):13-23.

Great Pyrenees Mix

**SEX**

Neutered Male

**AGE**

14 Years

**WEIGHT**

85 Pounds

**INTERPRETED BY**

Eric Lindquist, DMV,  
DABVP, Cert. IVUSS

**HOSPITAL NAME**

Q Street AH

**REFERRING VET**

Dr. Bretschneider

**INVOICE NUMBER**

14668

**DATE**

4/8/22